IQVIA Holdings (IQV) traded sharply higher on Monday, May 4, 2026, extending an earnings-week run-up as investors positioned ahead of the company’s first-quarter results due before the market opens Tuesday, May 5. The rally comes amid elevated focus on whether improving pharma funding and trial activity can translate into steadier near-term growth and a more confident full-year outlook.

With Q1 earnings imminent, the market’s attention has shifted to headline revenue and adjusted EPS, plus any read-through on bookings, backlog conversion, and customer behavior across large pharma, biotech, and medtech. Previews circulating today centered on expectations for Q1 revenue around $4.1 billion (mid-single-digit year-over-year growth) and framed the quarter as a key checkpoint for 2026 guidance credibility and demand normalization after prior volatility in the CRO and healthcare analytics space.

After the run-up, the immediate risk is that results meet expectations but commentary disappoints on the pace of reacceleration, especially around trial starts and backlog conversion. On the upside, investors are likely to reward any signs of stronger-than-expected order flow, stabilization in biotech demand, improving margins, and clear evidence that IQVIA’s tech and AI-related offerings are supporting productivity and client retention into the second half of 2026.